Table 3.
Clinical and laboratory differences between baseline and the end of ketogenic phase
| Parameters | Baseline | End of phase 1 | p value |
|---|---|---|---|
| Weight (kg) | 94.38 ± 17.34 | 87.29 ± 15.99 | < 0.001 |
| BMI (kg/m2) | 34.98 ± 5.43 | 32.35 ± 5.02 | < 0.001 |
| WC (cm) | 106.16 ± 14.20) | 99.24 ± 13.57 | < 0.001 |
| HC (cm) | 120.53 ± 10.81 | 115.91 ± 9.70 | < 0.001 |
| WHR | 0.88 ± 0.08 | 0.86 ± 0.09 | < 0.001 |
| Blood Glucose (mg/dL) | 88.04 ± 8.95 | 82.60 ± 10.08 | 0.072 |
| Insulin (mg/dL) | 17.35 ± 13.83 | 8.05 ± 5.48 | 0.286 |
| HOMA—IR | 3.80 ± 2.79 | 1.74 ± 1.29 | 0.332 |
| Tot Chol (mg/dL) | 170.20 ± 40.77 | 144.72 ± 30.61 | < 0.001 |
| LDL Chol (mg/dL) | 101.95 ± 29.11 | 81.40 ± 29.91 | 0.142 |
| HDL Chol (mg/dL) | 52.24 ± 12.17 | 49.86 ± 13.11 | 0.018 |
| TG (mg/dL) | 88.95 ± 30.77 | 86.14 ± 20.57 | 0.235 |
| GFR (mL/min) | 94.13 ± 19.00 | 89.00 ± 20.83 | 0.123 |
| Creatinine (mg/dL) | 0.77 ± 0.11 | 0.82 ± 0.16 | < 0.001 |
| Azotemia (mg/dL) | 30.44 ± 8.94 | 34.89 ± 10.60 | 0.001 |
| Uricemia (mg/dL) | 5.29 ± 1.45 | 6.23 ± 1.69 | 0.054 |
| AST (U/L) | 20.50 ± 6.60 | 20.92 ± 6.32 | 0.022 |
| ALT (U/L) | 23.43 ± 9.85 | 22.90 ± 12.15 | 0.001 |
| GGT (U/L) | 17.82 ± 6.48 | 14.72 ± 5.25 | 0.003 |
| Calcemia (mg/dL) | 9.70 ± 0.75 | 9.90 ± 0.61 | 0.056 |
| Sodiemia (mmol/L) | 140.34 ± 2.72 | 140.53 ± 2.22 | 0.001 |
| Potassiaemia (mmol/L) | 4.41 ± 0.30 | 4.43 ± 0.33 | 0.452 |
Data are expressed as n or mean ± SD
BMI body mass index, WC waist circumference, HC hip circumference, WHR waist-to-hip-ratio, HOMA-IR homeostasis model of assessment-IR, Tot Chol total cholesterol, LDL-chol low-dense-lipoprotein cholesterol, HDL-chol high dense lipoprotein cholesterol, TG triglycerides, GFR glomerular filtration rate, AST aspartate aminotransferase, ALT alanine transaminase, GGT gamma-glutamyl transferase